RxDoctor Payments Data

Rosa Wright, PA

Physician Assistant · Templeton, CANPI 1851829931

Payments from drug & device makers

$372in general payments, 2019–2025

Across 9 payments — averaging $41.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$125
  • AbbVie$88
  • Ardelyx, Inc.$55
  • Travere Therapeutics, Inc.$48
  • Braintree Laboratories, Inc.$23
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$21
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$372100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$372 in reported general payments places this provider in the 55th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$74,306
Medicare patients
448
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulancePlecanatide45$29,675
LinzessLinaclotide50$27,113
MotegrityPrucalopride Succinate19$20,312
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates179$11,873
MovantikNaloxegol Oxalate12$6,952
Pantoprazole Sodium316$3,484
Lubiprostone20$3,472
Omeprazole340$3,066
Esomeprazole Magnesium30$1,403
CholestyramineCholestyramine (With Sugar)21$1,153
Famotidine103$1,086
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl35$569
Lansoprazole23$506
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl29$394
Dicyclomine Hcl23$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$21$29,67545 claims
AbbVieLinzess$88$27,11350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Templeton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →